Unimolecular Triagonist Polypeptide Development
Budget: $750 – $1,500 USD
We are a biotechnology startup developing a novel unimolecular polypeptide therapeutic for obesity and related metabolic disorders. The construct integrates multiple synergistic mechanisms into a single long-acting agent suitable for biweekly injection. The multi agonist is not GLP-1 based.
We are seeking an experienced scientist or consultant to provide a scientific and mechanistic review of our therapeutic approach/design, focusing on translational feasibility, pharmacologic rationale, and development strategy.
Ideal candidates will meet the following criteria:
Clinical endocrinologist, physician-scientist, or MD–PhD with deep experience in obesity pharmacotherapy or metabolic peptide therapeutics or Neuroscientist with expertise in the gut-brain axis, appetite regulation, or peripheral satiety signaling.
Direct experience in drug development involving multi-agonist peptides for obesity, diabetes, or other metabolic disorders.
Familiarity with multi-agonist peptide therapeutics.
Ability to critically assess mechanism of action, safety, receptor targeting, and PK/PD strategy.
Highly Regarded (but not mandatory):
Former employment at Novo Nordisk, Eli Lilly, or Amylin Pharmaceuticals in R&D, clinical development, or translational science roles.
Scope of Work:
Review a ~10-page confidential technical document describing our therapeutic approach and underlying rationale.
Provide detailed feedback (written or verbal) on:
Mechanistic coherence
Clinical plausibility
Design risks and opportunities for refinement
Estimated time commitment: 3–5 hours total.
Requirements:
PhD, MD, or equivalent background in pharmacology, endocrinology, peptide drug development, or related field.
Must be willing to sign a Non-Disclosure Agreement (NDA) prior to document access.
CV or LinkedIn profile required for evaluation.
Preferred Experience:
Published work or patents in multi-agonist therapeutics or metabolic drug design.
Prior industry experience in obesity or peptide-based drug development.
Timeline:
Review to be completed within 1–2 weeks of engagement.
We are seeking an experienced scientist or consultant to provide a scientific and mechanistic review of our therapeutic approach/design, focusing on translational feasibility, pharmacologic rationale, and development strategy.
Ideal candidates will meet the following criteria:
Clinical endocrinologist, physician-scientist, or MD–PhD with deep experience in obesity pharmacotherapy or metabolic peptide therapeutics or Neuroscientist with expertise in the gut-brain axis, appetite regulation, or peripheral satiety signaling.
Direct experience in drug development involving multi-agonist peptides for obesity, diabetes, or other metabolic disorders.
Familiarity with multi-agonist peptide therapeutics.
Ability to critically assess mechanism of action, safety, receptor targeting, and PK/PD strategy.
Highly Regarded (but not mandatory):
Former employment at Novo Nordisk, Eli Lilly, or Amylin Pharmaceuticals in R&D, clinical development, or translational science roles.
Scope of Work:
Review a ~10-page confidential technical document describing our therapeutic approach and underlying rationale.
Provide detailed feedback (written or verbal) on:
Mechanistic coherence
Clinical plausibility
Design risks and opportunities for refinement
Estimated time commitment: 3–5 hours total.
Requirements:
PhD, MD, or equivalent background in pharmacology, endocrinology, peptide drug development, or related field.
Must be willing to sign a Non-Disclosure Agreement (NDA) prior to document access.
CV or LinkedIn profile required for evaluation.
Preferred Experience:
Published work or patents in multi-agonist therapeutics or metabolic drug design.
Prior industry experience in obesity or peptide-based drug development.
Timeline:
Review to be completed within 1–2 weeks of engagement.
Related categories:
Research
Biotechnology
Research Writing
Local Job
Research and Development
Technical Documentation